Rebecca Dent
@RebeccaDSing
Followers
1K
Following
557
Media
19
Statuses
418
RT @drsarahsam: I would agree! . Early detection and improved therapies including immunotherapy have made early stage TNBC curable for most….
0
5
0
RT @LLicata88: 🚨Just out in @CCR_AACR our analysis on the recurrence timing after neoadjuvant chemo-immunotherapy in early-stage TNBC. We a….
0
11
0
RT @sophiawongyn: Thank you for all the support 👏🏼🙏🏼@danieltanmd @RebeccaDSing @ravikanesvaran @DrGopalIyer @yahwee_t @EvelynWongYT @Shutin….
0
1
0
RT @drsarahsam: Throwback Thursday. Reminding myself of the bevacizumab saga in advanced breast cancer. Bispecific VEGF/PDL-1 inhibitor….
0
5
0
RT @MyriamChalabi: Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NS….
nature.com
Nature Cancer - In this Review, Chalabi and colleagues summarize the current clinical landscape of neoadjuvant immunotherapy in solid tumors.
0
61
0
RT @tompowles1: Thanks to the whole @Annals_Oncology team, @FAndreMD & all the authors for driving up the quality of the journal (IF64)….
0
9
0
RT @eriksahailab: Excited to share our new study on how resistance to AKT inhibition is linked to lineage differences within breast cancer….
0
27
0
RT @drdaviddwlee: ASCO 2025. Proud to co-author a poster, networked with global experts and caught up with friends in the oncology communi….
0
2
0
RT @DrYukselUrun: Timely and much-needed recommendations from @ASCO .We hope academic medical centers implement them without delay—for the….
0
17
0
RT @matteolambe: One more @NEJM paper for the #BreastCancer community at #ASCO25: very important data with use of #elinzanetant to help pat….
0
22
0
RT @DrSGraff: With synchronous publication in @NEJM, Fatima Cardoso @ABCGlobalAll shows Elinzanetant reduces vasomotor symptoms (hot flashe….
0
34
0
RT @marklewismd: Are T-cells "morning people"?!. Chronotherapeutic oncology always makes me marvel at the staggering number of variables to….
0
11
0
RT @ADetsky: The potential impact of this RCT is huge. First one to prove that exercise has benefits equal to many standard treatments for….
nejm.org
Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...
0
25
0
RT @oncology_bg: Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronge….
0
64
0
RT @BianchiniGP: 🔥 #ASCO25 Re-challange with Trastuzumab Deruxtecan after grade 1 ILD is overall safe in a real-world population . Some of….
0
14
0
RT @PTarantinoMD: Impressive phase 2 data with the Trop2 ADC Sac-TMT for 1L mTNBC (n=41): ORR 70%, mPFS 13.4 months. High activity irrespec….
0
39
0
RT @DrHBurstein: I think that's probably correct. In 2nd line, SC > chemo. By the additive property, we now see that SG + pembro > chemo….
0
11
0
RT @DrHBurstein: very interesting data from RCT that exercise reduces recurrence and improves OS in early colon cancer. We've waited a lon….
nejm.org
Preclinical and observational studies suggest that exercise may improve cancer outcomes. However, definitive level 1 evidence is lacking. In this phase 3, randomized trial conducted at 55 centers, ...
0
18
0